Anticancer potential of methanolic extracts from Pleurotus species on raji cells and antibacterial activity against Methicillin-Resistant Staphylococcus aureus

Abstract. Prastiyanto ME, Rukmana RM, Saraswati DK, Darmawati S, Maharani ETW, Tursinawati Y. 2020. Anticancer potential of methanolic extracts from Pleurotus species on raji cells and antibacterial activity against Methicillin-Resistant Staphylococcus aureus. Biodiversitas 21: 5644-5649. The aim of this work is to identify the potential effects of methanolic extracts from four species of the Pleurotus genus cultivated in Indonesia on nasopharynx cancer (Raji cell line), and to investigate their antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). This study investigates four species members of Pleurotus (Pleurotus ostreatus, P. cystidiosus, P. flabellatus, and P. pulmonarius var. stechangii). Dry Samples were extracted with methanol to yield crude extracts. Cytotoxicity screening was conducted using MTT assay of dry extracts, while antibacterial activity was calculated based on the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) using Mueller–Hinton broth, via the microdilution method. Compounds were analyzed using thin-layer chromatography (TLC). P. flabellatus provided the highest yield of dry extract (20.8%) with the lowest value of IC50 (556.226 µg/mL) compared to the three other species investigated. Antibacterial activity was calculated as MIC and MBC values against MRSA by the P. flabellatus extract which reached 6.25 mg/mL and 250 mg/mL, respectively. The result of TLC of the dry extract of P. flabellatus revealed the presence of terpenoids. P. flabellatus has the potential to be developed as both an anti-cancer and an antibacterial agent, especially against Raji cells and MRSA strains. However, further in vivo research and discovery of the modes of action involved are still needed to shed light on these effects. Studies can provide new information about the benefits of Pleurotus as a source of natural anticancer and antibacterial compound.

Download Full-text

In Vivo Antibacterial Activity of S-3578, a New Broad-Spectrum Cephalosporin: Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa Experimental Infection Models

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.47.8.2507-2512.2003 ◽

2003 ◽

Vol 47 (8) ◽

pp. 2507-2512 ◽

Cited By ~ 24

Author(s):

Masakatsu Tsuji ◽

Morio Takema ◽

Hideaki Miwa ◽

Jingoro Shimada ◽

Shogo Kuwahara

Keyword(s):

Staphylococcus Aureus ◽

Pseudomonas Aeruginosa ◽

Antibacterial Activity ◽

Methicillin Resistant Staphylococcus Aureus ◽

Pulmonary Infections ◽

Methicillin Resistant ◽

Infection Models ◽

Systemic Infections

ABSTRACT The in vivo antibacterial activity of S-3578, a new parental cephalosporin, was compared with those of cefepime, ceftriaxone, ceftazidime, imipenem-cilastatin, and vancomycin. The efficacy of S-3578 against systemic infections caused by methicillin-resistant Staphylococcus aureus (MRSA) SR3637 (50% effective dose [ED50], 7.21 mg/kg of body weight) was almost the same as that of vancomycin. In contrast, cefepime and imipenem-cilastatin were less active against this pathogen (ED50s, >100 and >100 mg/kg, respectively). S-3578 was the most effective compound against penicillin-resistant Streptococcus pneumoniae SR20946 (ED50, 1.98 mg/kg). S-3578 (10 mg/kg) induced a significant reduction in the numbers of viable MRSA SR17764 and Pseudomonas aeruginosa SR10396 organisms in polymicrobial pulmonary infections. The therapeutic efficacy of S-3578 was more potent than that of the combination of vancomycin and ceftazidime. High levels of S-3578 were detected in plasma in vivo, and its efficacy against experimentally induced infections in mice caused by MRSA and P. aeruginosa reflected its potent in vitro activity. We conclude that S-3578 is a promising new cephalosporin for the treatment of infections caused by gram-positive and -negative bacteria, including MRSA and P. aeruginosa.

Download Full-text

Antibacterial activity of unifloral honeys against clinical isolates of methicillin-resistant Staphylococcus aureus

Planta Medica ◽

10.1055/s-0029-1234974 ◽

2009 ◽

Vol 75 (09) ◽

Author(s):

A Hannan ◽

MB Hussain ◽

M Absar

Keyword(s):

Staphylococcus Aureus ◽

Antibacterial Activity ◽

Methicillin Resistant Staphylococcus Aureus ◽

Clinical Isolates ◽

Methicillin Resistant

Download Full-text

In vitro antibacterial activity of some spice extracts against methicillin-resistant Staphylococcus aureus isolated from nose of food handlers

International Journal of Pharmaceutical Research ◽

10.31838/ijpr/2020.12.03.412 ◽

2020 ◽

Vol 12 (03) ◽

Keyword(s):

Staphylococcus Aureus ◽

Antibacterial Activity ◽

Methicillin Resistant Staphylococcus Aureus ◽

Food Handlers ◽

Methicillin Resistant ◽

In Vitro Antibacterial Activity

Download Full-text

Preliminary analysis of the antimicrobial activity of a novel surgical incise drape containing chlorhexidine gluconate against methicillin-resistant Staphylococcus aureus (MRSA) in an in vivo porcine, incisional-wound model

American Journal of Infection Control ◽

10.1016/j.ajic.2021.01.016 ◽

2021 ◽

Author(s):

Neal Carty ◽

David Leaper ◽

Larry Perry ◽

Charles E. Edmiston

Keyword(s):

Staphylococcus Aureus ◽

Antimicrobial Activity ◽

Preliminary Analysis ◽

Methicillin Resistant Staphylococcus Aureus ◽

Chlorhexidine Gluconate ◽

Methicillin Resistant ◽

Wound Model

Download Full-text

Group V Phospholipase A2 Mediates Endothelial Dysfunction and Acute Lung Injury Caused by Methicillin-Resistant Staphylococcus aureus

Cells ◽

10.3390/cells10071731 ◽

2021 ◽

Vol 10 (7) ◽

pp. 1731

Author(s):

Yu Maw Htwe ◽

Huashan Wang ◽

Patrick Belvitch ◽

Lucille Meliton ◽

Mounica Bandela ◽

...

Keyword(s):

Staphylococcus Aureus ◽

Acute Lung Injury ◽

Endothelial Dysfunction ◽

Lung Injury ◽

Phospholipase A2 ◽

Methicillin Resistant Staphylococcus Aureus ◽

Group V ◽

Methicillin Resistant

Lung endothelial dysfunction is a key feature of acute lung injury (ALI) and clinical acute respiratory distress syndrome (ARDS). Previous studies have identified the lipid-generating enzyme, group V phospholipase A2 (gVPLA2), as a mediator of lung endothelial barrier disruption and inflammation. The current study aimed to determine the role of gVPLA2 in mediating lung endothelial responses to methicillin-resistant Staphylococcus aureus (MRSA, USA300 strain), a major cause of ALI/ARDS. In vitro studies assessed the effects of gVPLA2 inhibition on lung endothelial cell (EC) permeability after exposure to heat-killed (HK) MRSA. In vivo studies assessed the effects of intratracheal live or HK-MRSA on multiple indices of ALI in wild-type (WT) and gVPLA2-deficient (KO) mice. In vitro, HK-MRSA increased gVPLA2 expression and permeability in human lung EC. Inhibition of gVPLA2 with either the PLA2 inhibitor, LY311727, or with a specific monoclonal antibody, attenuated the barrier disruption caused by HK-MRSA. LY311727 also reduced HK-MRSA-induced permeability in mouse lung EC isolated from WT but not gVPLA2-KO mice. In vivo, live MRSA caused significantly less ALI in gVPLA2 KO mice compared to WT, findings confirmed by intravital microscopy assessment in HK-MRSA-treated mice. After targeted delivery of gVPLA2 plasmid to lung endothelium using ACE antibody-conjugated liposomes, MRSA-induced ALI was significantly increased in gVPLA2-KO mice, indicating that lung endothelial expression of gVPLA2 is critical in vivo. In summary, these results demonstrate an important role for gVPLA2 in mediating MRSA-induced lung EC permeability and ALI. Thus, gVPLA2 may represent a novel therapeutic target in ALI/ARDS caused by bacterial infection.

Download Full-text